Abstract
Purpose: The aim of the study is to compare the tumor-specific targeting, pharmacokinetics, and biodistribution of 64Cu- DOTA-HB22.7 when administered to xenograft-bearing mice intravenously (IV), intraperitoneally (IP), and subcutaneously (SQ). Procedures: Mice bearing human non-Hodgkin's lymphoma (NHL) xenografts were injected IV, IP, or SQ with 64Cu-DOTA-HB22.7. Xenograft targeting was evaluated by micro positron emission tomography (microPET) and confirmed by organ biodistribution studies. Blood measurements of 64Cu were performed to determine the pharmacokinetics and clearance of 64Cu-DOTA-HB22.7. Results: 64Cu-DOTA-HB22.7 demonstrated equivalent tumor targeting within 24-48 h, regardless of the route of administration. Organ biodistribution confirmed tumor-specific targeting. Blood pharmacokinetics demonstrated that 64Cu-DOTA-HB22.7 accessed the bloodstream after IP and SQ administration to a similar degree as IV administration, albeit at a slower rate. Conclusions: These findings establish 64Cu-DOTA-HB22.7 as a potential radioimmunotherapeutic and/or NHL-specific imaging agent. These findings provide evidence that IP and SQ administration can achieve results equivalent to IV administration and may lead to more efficient, reproducible treatment plans for antibody-based therapeutics.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 79-87 |
| Number of pages | 9 |
| Journal | Molecular Imaging and Biology |
| Volume | 11 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2009 |
Fingerprint
Keywords
- Cu
- CD22
- HB22.7
- Non-Hodgkin's lymphoma
- PET
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Radiology Nuclear Medicine and imaging
Cite this
Imaging and pharmacokinetics of 64Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-hodgkin's lymphoma xenografts. / Martin, Shiloh M.; O'Donnell, Robert T; Kukis, David L.; Abbey, Craig K.; McKnight, Hayes; Sutcliffe, Julie; Tuscano, Joseph.
In: Molecular Imaging and Biology, Vol. 11, No. 2, 2009, p. 79-87.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Imaging and pharmacokinetics of 64Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-hodgkin's lymphoma xenografts
AU - Martin, Shiloh M.
AU - O'Donnell, Robert T
AU - Kukis, David L.
AU - Abbey, Craig K.
AU - McKnight, Hayes
AU - Sutcliffe, Julie
AU - Tuscano, Joseph
PY - 2009
Y1 - 2009
N2 - Purpose: The aim of the study is to compare the tumor-specific targeting, pharmacokinetics, and biodistribution of 64Cu- DOTA-HB22.7 when administered to xenograft-bearing mice intravenously (IV), intraperitoneally (IP), and subcutaneously (SQ). Procedures: Mice bearing human non-Hodgkin's lymphoma (NHL) xenografts were injected IV, IP, or SQ with 64Cu-DOTA-HB22.7. Xenograft targeting was evaluated by micro positron emission tomography (microPET) and confirmed by organ biodistribution studies. Blood measurements of 64Cu were performed to determine the pharmacokinetics and clearance of 64Cu-DOTA-HB22.7. Results: 64Cu-DOTA-HB22.7 demonstrated equivalent tumor targeting within 24-48 h, regardless of the route of administration. Organ biodistribution confirmed tumor-specific targeting. Blood pharmacokinetics demonstrated that 64Cu-DOTA-HB22.7 accessed the bloodstream after IP and SQ administration to a similar degree as IV administration, albeit at a slower rate. Conclusions: These findings establish 64Cu-DOTA-HB22.7 as a potential radioimmunotherapeutic and/or NHL-specific imaging agent. These findings provide evidence that IP and SQ administration can achieve results equivalent to IV administration and may lead to more efficient, reproducible treatment plans for antibody-based therapeutics.
AB - Purpose: The aim of the study is to compare the tumor-specific targeting, pharmacokinetics, and biodistribution of 64Cu- DOTA-HB22.7 when administered to xenograft-bearing mice intravenously (IV), intraperitoneally (IP), and subcutaneously (SQ). Procedures: Mice bearing human non-Hodgkin's lymphoma (NHL) xenografts were injected IV, IP, or SQ with 64Cu-DOTA-HB22.7. Xenograft targeting was evaluated by micro positron emission tomography (microPET) and confirmed by organ biodistribution studies. Blood measurements of 64Cu were performed to determine the pharmacokinetics and clearance of 64Cu-DOTA-HB22.7. Results: 64Cu-DOTA-HB22.7 demonstrated equivalent tumor targeting within 24-48 h, regardless of the route of administration. Organ biodistribution confirmed tumor-specific targeting. Blood pharmacokinetics demonstrated that 64Cu-DOTA-HB22.7 accessed the bloodstream after IP and SQ administration to a similar degree as IV administration, albeit at a slower rate. Conclusions: These findings establish 64Cu-DOTA-HB22.7 as a potential radioimmunotherapeutic and/or NHL-specific imaging agent. These findings provide evidence that IP and SQ administration can achieve results equivalent to IV administration and may lead to more efficient, reproducible treatment plans for antibody-based therapeutics.
KW - Cu
KW - CD22
KW - HB22.7
KW - Non-Hodgkin's lymphoma
KW - PET
UR - http://www.scopus.com/inward/record.url?scp=60049099141&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=60049099141&partnerID=8YFLogxK
U2 - 10.1007/s11307-008-0148-1
DO - 10.1007/s11307-008-0148-1
M3 - Article
C2 - 18949521
AN - SCOPUS:60049099141
VL - 11
SP - 79
EP - 87
JO - Molecular Imaging and Biology
JF - Molecular Imaging and Biology
SN - 1536-1632
IS - 2
ER -